Department: DS/ML (Data Science/Machine Learning)
Employment Type: Full Time
Location: San Mateo, CA
The role: We are seeking a creative, ambitious Machine Learning Scientist or Engineer to advance the state of the art in ML-driven therapeutic antibody design.
At BigHat Biosciences our full-stack antibody drug development platform uses AI/ML to drive every stage from discovery to optimization. Our roboticized high-throughput wet-lab continually adds to our large proprietary datasets, which are piped through a custom LIMS++ data management and orchestration layer to automatically update and deploy the latest models. This makes development of complex, net-gen therapeutics ‘trivially parallelizable’, at a pace which only accelerates as we develop better ML tooling.
You’re not interested in just git-cloning the latest NeurIPS pub and swapping out the dataset. Motivated by an enthusiasm for the possibility of addressing unmet patient need, and a curiosity about the underlying biology, you’ll apply your top-tier ML skillset to refine and expand this state of the art protein engineering platform. Success will mean not only hands-on methods development, but actively participating in the application of our platform to the accelerated design of new drugs for devastating diseases.
The salary estimated for this position is $150,000 - $200,000 + bonus + options + benefits. Compensation will vary depending on job-related knowledge, skills, and experience. Actual compensation will be confirmed in writing at the time of the offer.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
BigHat is backed by Section 32, Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.